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Violeta Moya-Alvarez1,2,3*, Rosa Abellana4 and Michel Cot1,2Abstract
Albeit pregnancy-associated malaria (PAM) poses a potential risk for over 125 million women each year, an accurate
review assessing the impact on malaria in infants has yet to be conducted. In addition to an effect on low birth weight
(LBW) and prematurity, PAM determines foetal exposure to Plasmodium falciparum in utero and is correlated to
congenital malaria and early development of clinical episodes during infancy. This interaction plausibly results from an
ongoing immune tolerance process to antigens in utero, however, a complete explanation of this immune process
remains a question for further research, as does the precise role of protective maternal antibodies. Preventive
interventions against PAM modify foetal exposure to P. falciparum in utero, and have thus an effect on perinatal malaria
outcomes. Effective intermittent preventive treatment in pregnancy (IPTp) diminishes placental malaria (PM) and its
subsequent malaria-associated morbidity. However, emerging resistance to sulphadoxine-pyrimethamine (SP) is
currently hindering the efficacy of IPTp regimes and the efficacy of alternative strategies, such as intermittent screening
and treatment (IST), has not been accurately evaluated in different transmission settings. Due to the increased risk of
clinical malaria for offspring of malaria infected mothers, PAM preventive interventions should ideally start during the
preconceptual period. Innovative research examining the effect of PAM on the neurocognitive development of the
infant, as well as examining the potential influence of HLA-G polymorphisms on malaria symptoms, is urged to
contribute to a better understanding of PAM and infant health.
Keywords: Pregnancy-associated malaria, Immune tolerance, Intermittent preventive treatment in pregnancy,
Parasitaemia, Infancy, Sulphadoxine-pyrimethamineBackground
Pregnancy-associated malaria (PAM), defined as periph-
eral or placental infection by Plasmodium, presents as a
major public health concern due to significant adverse
health effects on both the mother and the foetus. Women
are increasingly susceptible to malaria infection during
pregnancy since Plasmodium falciparum, the most com-
mon parasite responsible for malaria, avoids spleen clear-
ance through expression of proteins that bind to the
chondroitin sulphate A (CSA) in the placental intervillous
space [1-3]. Consequently, the foetus is initially exposed to* Correspondence: vmoyaalvarez@gmail.com
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article, unless otherwise stated.malaria in utero. Epidemiological studies estimate 125 mil-
lion pregnancies are at risk of malaria infection every year
[4] within a purposed estimate of 32 million women who
become pregnant every year in malaria endemic sub-
Saharan Africa countries [5].
The effects of pregnancy-associated malaria on infants
include stillbirth, congenital malaria, foetal anaemia, and
low birth weight (LBW), caused by intra-uterine growth
retardation (IUGR) and pre-term delivery [6-11]; consider-
ing the subsequent adverse health outcomes PAM related
deaths would account for 75,000 to 200,000 infant deaths
in sub-Saharan Africa [12].
Ultimately, pregnancy-associated malaria determines
foetal exposure to P. falciparum in utero. Indeed, placental
malaria is identified as a significant indicator for increased
susceptibility to malaria during infancy [13-18]. In turn,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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arum in utero.
The prevalence of PAM is influenced by transmission,
the immunity of the mother, and protective measures,
such as insecticide-treated nets (ITNs) or intermittent
preventive treatment in pregnancy (IPTp) [10]. Despite
the considerable literature on PAM epidemiological and
clinical outcomes, no clear conclusions regarding PAM’s
effect on malaria in infants have been accurately reported.
Further well-known risk factors for malaria in infants in-
clude high transmission or HIV co-morbidity [19], but ex-
ploring PAM influence on malaria risk during infancy
could significantly contribute to better understand Plas-
modium infection among infants. This review aims to re-
visit the present evidence on pregnancy-related factors
that influence malaria in infants, including the effect of
control interventions and novel research perspectives. Re-
sults are presented by the following topic areas: the epi-
demiological evidence on the effect of PAM on malaria in
the offspring, the risk factors determining exposure to
Plasmodium in utero, with special regard to control inter-
ventions, such as IPTp and ITNs, and the influence of the
increasing resistance to SP-IPTp on malaria perinatal out-
comes. Finally, new research perspectives to examine the
effect of PAM on infant health are discussed.
Methods: search strategy and selection criteria
A systematic literature specifying the epidemiology of
malaria in infants with a focus on malaria risk factors in
infants, was realized between the 10th January 2012 and
the 9th June 2014 utilizing PubMed, the Cochrane Li-
brary, Global Health and World Health Organization re-
gional databases. In total, 1,136 articles in English,
French, Spanish and Portuguese were classified for re-
view. A combination of standardized terms were used as
search criteria; concerning PubMed, the search terms
utilized were the Medical Subjects Headings (MeSH)
“Parasitaemia” OR “Malaria” OR “Anaemia”. In addition,
complementary articles, reports, and studies were identi-
fied through review and citations. Search criteria for
relevant PAM and IPTp studies accepted all designs with
the sole caveat that they originated from a malaria en-
demic country. Three-hundred and fifty-five articles
were selected for final review. Due to the limited num-
ber of studies and reviews, no sensitivity analysis was re-
alized. No date restrictions were applied and publication
bias was not addressed.
Pregnancy-associated malaria and malaria in infants:
epidemiological evidence
Pregnancy-associated malaria is consistently associated
with an increased malaria risk during infancy [13-16,18]
and has been associated with congenital malaria, increased
malaria episodes, anaemia, and non-malaria fever episodesin infants [10,20]. The principal findings of several
reviewed studies are presented in Table 1.
Congenital malaria, defined as the presence of asexual
P. falciparum parasites in the cord blood or in the per-
ipheral blood during the first week of life [25], is the re-
sult of transplacental transmission of parasites just
before or during delivery. Congenital malaria rates range
between 0.83 and 5.96% [17,25-29] in recent epidemio-
logical studies. The introduction of molecular techniques
has increased the detection of cord blood parasitaemia
raising prevalence rates to 33% [30]. Congenital malaria
might entail clinically relevant symptoms in some cases,
such as high fever and convulsions, anaemia, hepatosple-
nomegaly, jaundice, anorexia, vomiting, diarrhoea, drow-
siness, pallor, respiratory distress, and cyanosis [30,31].
Although congenital malaria is an important factor in
the differential diagnostic of neonatal fever in endemic
countries, severe symptoms are rare and, hence, it does
not appear to constitute an epidemic at present.
PAM is also associated with earlier episodes, as well as
overall clinical malaria episodes, in infants [13-15,17,23].
In a landmark longitudinal cohort study of infants in
Cameroon, placental P. falciparum infection was associ-
ated with infant malaria between four and six months,
and parasitaemia rates were higher between five to eight
months in offspring of placenta-infected mothers com-
pared to offspring of mothers without placental infection
independently of congenital infection [13] (at 6 months:
PM+: 36%; PM-: 14%, p < 0.05). A study in Tanzania
found an interaction between gravidity and placental
malaria. The findings demonstrated that the offspring of
multigravid women with placental malaria had the high-
est odds of subsequent malaria episodes (Adjusted Odds
Ratio (AOR = 1.59) 95% confidence interval (CI) 1.16–
2.17) [14], and the lowest odds were attributed to off-
spring of primigravid placenta infected mothers.
Regarding the early appearance of parasites in infants,
the above mentioned study in Tanzania reported a 1.41
estimated hazard ratio (HR) (95% CI 1.01–1.99) of first
parasitaemia for offspring of mothers with P. falciparum
placental infection after adjusting for gravidity, transmis-
sion season at time of birth, area of residence, and bed
net usage [14]. In Gabon, a significant correlation be-
tween placental malaria and the first malaria episode
was also found (adjusted HR (AHR) = 2.1; 95% CI 1.2–
3.7) after adjustment for gravidity, season of birth, area
of residence, IPTp versus placebo, and ITNs [15]. A
more recent study in Mozambique found that infants
born to women who had clinical malaria during preg-
nancy, or acute placental infection, had an increased risk
of clinical malaria during infancy (OR = 1.96; 95% CI,
1.13–3.41, and OR = 4.63; 95% CI 2.10–10.24, respect-
ively) [22]. Furthermore, a cohort study conducted in
Tori Bossito (Benin) confirmed the link between PM
Table 1 Influence of maternal parasitemia on malaria in infants
Cohort
Study
design and
simple size
Time
period
Transmission
setting
Malaria
prevention
strategy
during
pregnancy
Treatment
drug
regime
Proportion of
maternal
peripheral
parasitemia at
delivery
Proportion of
placental
parasitemia
Proportion of
neonatal
parasitemia
Infant
follow-
up
period
Median time
to first
parasitemia
(days, min,
max)
Association of
infant malaria
with PAM
Early infant
parasitemia
<3 months
Mangochi
[21] (Malawi)
Clinical trial on
comparative
efficacy of CQ
or MQ; infant
cohort follow-
up (1766
women at
delivery and
1289 infants)
1988-1990
Perennial with
seasonal peaks
CQ and MQ CQ
CQ: 20.3%
MQ: 4.1%
CQ: 25.1%
MQ: 6.2%
CQ: 8.6%
MQ: 3.1%
12
months
199 (192-207)
at 3 months: 1.1
(0.7-1.9)
18.5%
Ebolowa [13]
(Cameroon)
Infant cohort
follow-up
(197)
1993-1995
Perennial with
seasonal peaks
CQ CQ
22.84%
(Primigravid:
69%;
Multigravid:
31%)
24
months
PM+: 217;
PM-:350
at 6 months:
PM+: 36%; PM-:
14%, p<0.05 at 2
years: PM+:
46.5%; PM-:
38.5%, p=0.6
≈12%
Muheza [14]
(Tanzania)
Infant cohort
follow-up
(453)
2002-2004
Perennial with
seasonal peaks
(400 infective
mosquito
bites each
year)
SP (area
with 68%
resistance
14-day
treatment
failure rate)
15.2%
(Primigravid≤2:
24%;
Multigravid>2:
5.6%)
12
months
266 (238–294)
PM-:273 (245-
322) PM+: 244
(147-266);
Primigravidae:
PM+:AOR=
0.21, (0.09–0.47)
PM-: Refer
ence*** Multi
gravidae: PM+:
AOR =1.59,
(1.16–2.17)
PM-:AOR=0.67,
(0.50–0.91)
PM+ ≈20%;
PM-≈10%
Lambarené
[15] (Gabon)
Infant cohort
follow-up
(527)
2002-2004 Perennial No 10.5%* 9.48%
30
months
Primigravidae:
PM+:107 (83-
139) PM-:102
(29-205) Multi-
gravidae: PM
+:111 (13-189)
PM-:92 (27-
208)
PM+:AOR= 2.1,
(1.2–3)
PM-: Reference**
PM+ ≈2%;
PM-≈0%
Manhiça [22]
(Mozambique)
Clinical trial on
the efficacy of
SP compared
to placebo;
infant cohort
follow-up
(1030 women
at delivery and
997 infants)
2003-2005
Perennial with
seasonal peaks
ITNs vs
ITNs+SP
SP-AQ
ITNs+
placebo:15.15%
ITNs+SP: 7.1%
ITNs+
placebo:52.27%
ITNs+SP:
52.11%
ITNs+
placebo:1.15%
ITNs+SP:
0.92%
12
months
Clinical PAM:
AOR=1.96 (1.13–
3.41) Acute PM:
AOR= 4.63 (2.1-
10.24) Chronic
PM: AOR=3.95
(2.07-7.55)
PM-: Reference
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Table 1 Influence of maternal parasitemia on malaria in infants (Continued)
Tori Bossito
[17,23] (Benin)
Infant cohort
follow-up
(550)
2007-2008
Perennial with
seasonal peaks
(400 infective
mosquito
bites each
year)
SP AL 11% 0.83%
12
months
PM+: 34
(4-83); PM-:
43 (4-85)
ITN:AOR=2.13
(1.24–3.67) No
ITN: AOR=1.18
(0.60–2.33)
20.3%
Mono [24]
(Benin)
Mother and
infant cohort
follow-up
(218)
2008-2010
Mesoendemic
(1-35 bites/
person/year)
SP
Quinine or
SP
3.67%
12
months
PAM+: 362
(18-390) PAM-:
365 (64-449)
PAM during the
3rd trimester of
pregnancy:
AOR= 4.6 (1.7;
12.5) PAM
during the 1st
and 2nd
trimesters non
significant
PM: Placental malaria, PAM: Pregnancy associated malaria and AOR: Adjusted Odds Ratio.
*data from a reference article.
**the association between placental malaria and malaria in the child was only statistically significant for children who were randomized to receive the sulphadoxine-pyrimethamine intervention (AHR=3 (1.5-6)).
***Analysis of the effect of IPTp on parasitemia of the offspring was performed for 882 women of this cohort. Among them, 21.6% received no IPTp, 42% one dose, and 36.4% two or more doses.
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and environmental follow-up [17,23]. The study findings
on infants sleeping in a house with an ITN confirmed the
link between PM and malaria controlled for transmission
intensity, seasonality, number of anopheles, antenatal care
(ANC) visits, and maternal severe anaemia (AHR = 2.13;
95% CI 1.24–3.67) compared with infants whose mothers
did not have placental malaria at delivery. This cohort
study additionally reports an increased susceptibility of in-
fants to P. falciparum parasites with antigens to which
they were previously exposed in utero suggesting an im-
mune tolerance process undergoing during pregnancy
[32]. PAM has also been associated with a reduction in
maternal antibody transfer to the foetus [33,34], hence
increasing infant susceptibility to parasites [35,36]. Con-
sistent with the notion that the type, timing, and the
duration of exposure to the parasite in utero determine
susceptibility to malaria, infections occurring during the
third trimester are associated with increased risk of in-
fection and clinical malaria during the first year of life
according to another study in the province of Mono
(South Benin) [24].
Nevertheless, the effect of PAM on infant health may
involve an overall increased morbidity and mortality.
Placental malaria was additionally correlated with non-
malaria infections in the Tori Bossito cohort infants dur-
ing the first 18 months of life suggesting that immune
tolerance could also imply immunity in a more general
manner besides malaria specific immunity [20]. More-
over, placental malaria posed a significant risk factor for
overall mortality during the first year of life [37] in a
study in Malawi, and another study from Mozambique
[22] identified both acute placental malaria and cord
blood parasitaemia with increased infant mortality. More
precisely, in this study from Mozambique infant mortal-
ity was also significantly associated with malaria infec-
tion of the placenta (p-value < 0.012) after adjustment on
HIV status, LBW, maternal clinical malaria during preg-
nancy, foetal anaemia and IPTp regime. The risk of
dying during infancy was increased among infants born
to women with acute placental infection (OR = 5.08; 95%
CI 1.77–14.53), as well as among infants with parasit-
aemia in the cord blood (OR = 19.31; 95% CI, 4.44–
84.02).
A possible explanation for different immune tolerance
effects of PAM relates to HLA-G polymorphisms and
their association with different malaria susceptibility
[38]. HIV infection influences as well a woman’s suscep-
tibility to malaria, and this is of major concern as both
diseases overlap considerably in sub-Saharan Africa.
Consistent evidence suggests both infections interact
synergistically and result in poorer health outcomes [39].
PAM is more frequent among HIV infected women in
comparison to non-infected women, and can increasematernal HIV load [40-42]. PAM in HIV-positive preg-
nant women is further associated with higher risk of
both anaemia and LBW [40,43-45]. This results in over-
all increased maternal and infant mortality [46,47].
A potential long-term consequence of PAM concerns
neuro-cognitive impairment of infants exposed to mal-
aria in utero. Due to recent evidence concerning the role
of the complement system in the regulation of neurode-
velopment, it has been proposed that excessive comple-
ment activation induced by placental malaria may
disrupt normal neurodevelopment resulting in neuro-
cognitive impairment of infants exposed to Plasmodium
in utero [48].
Although a complete explanation of the physiopathol-
ogy of PAM has not yet been understood, in utero ex-
posure to malaria is probably nonetheless correlated
with placental sequestration of erythrocytes. The im-
mune tolerance process would plausibly then depend on
the type of malaria antigen in contact with the foetus,
the amount and the duration of the exposure, and the
timing of exposure during pregnancy [16,49]. The inter-
action between gestation and infection timing during
pregnancy has been previously shown to influence the
pathologic consequences for the offspring. Due to the
particular physiopathology of PAM, a specific immunity
develops during the first pregnancy [10] and, hence,
primigravidae are at higher risk of PAM compared to
multigravidae [10]. In this respect, infants of primigravid
women are also at higher risk of subsequent malaria in
comparison to infants of multigravid women, mainly as
a result of reduced antibody transfer [11]. Finally the
timing of malaria episodes during pregnancy results in
different effects on both the mother and the foetus;
parasitaemia appears to be higher during the first and
second trimesters, even if follow-up on P. falciparum
parasitaemia during the first trimester has seldom been
complete [10,50-53]. Essentially, the administration of
IPTp at different moments determines different protec-
tion patterns for the infant [50] and, in parallel, a signifi-
cant reduction in placental malaria and maternal
parasitaemia has been extensively described [54] follow-
ing the implementation of PAM control interventions.
As a result of the different infant malaria outcomes de-
pending on PAM and IPTp, and considering the body of
the available research, the following questions are posed:
How does exposure in utero to P. falciparum influence
malaria in infants? How do control interventions modify
in turn the impact of PAM on clinical malaria in
infants?
Pregnancy associated malaria and control interventions:
effect on perinatal malaria outcomes
Foetal exposure to Plasmodium in utero primarily de-
pends on transmission and control interventions.
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between exposure and immunity. IPT is a widespread
preventive strategy to fight malaria and involves the ad-
ministration of a curative dose of an effective anti-
malarial drug, regardless of the presence of Plasmodium
in the blood, to prevent the disease [19]. IPT measures
decrease parasitaemia, and consequently influence the
immunity response of the infant to Plasmodium in utero
through maternal intermittent preventive treatment in
pregnancy (IPTp). Therefore, WHO recommends IPTp
with SP for all pregnant women as early as possible in
the second trimester, and at each scheduled antenatal
care visit at least one month apart in areas of moderate
to high malaria transmission [55], IPTp strategies are
however not yet completely deployed in malaria endemic
regions and the implementation of IPTp interventions
interfere with PAM outcomes. Figure 1 presents the main
characteristics concerning implementation of IPTp pro-
grammes in Africa.
Effective administration of IPTp clears placental parasit-
aemia and consequently modifies the exposure to malaria
antigens resulting in a significant reduction in placental
malaria and maternal parasitaemia [54]. Compared to case
management or placebo in pregnant women, a two-dose
IPTp regime with sulphadoxine-pyrimethamine (SP) sig-
nificantly reduced placental malaria according to a review
on four studies (relative risk (RR) = 0.48) [56]. In a ran-
domized, double blind, placebo-controlled trial with joint
use of ITNs in Mozambique, SP-IPTp (1-2 doses) was cor-
related to a significant decrease only in active placental
malaria [57] (Table 1). In Mali, placental parasitaemia was
significantly reduced by SP-IPTp (AOR = 0.69) when com-
pared to weekly administered chloroquine (CQ) [58] and
confirmed higher SP efficacy compared to CQ already re-
ported in Malawi [59]. A recent meta-analysis has con-
cluded significant reduction in PM after three doses of SP
compared to two doses [54], which corresponds to current
WHO recommendations.
A comprehensive review encompassing published studies
conducted between 1985 and 2000 found a PAM preva-
lence range of 10% to 65% among all gravidae [12], with a
median prevalence of 27.8% [10]. In low-transmission
African settings, the median prevalence peripheral infection
was 13.7% and the placental malaria median prevalence
was 6.7% [10]. Recent studies however reported a signifi-
cant decline in prevalence following PAM control interven-
tions. The protection of joint ITNs with IPTp-SP use is
significant in only certain trials, yet reported ITN use
ranges from 5 to 25%, and this might not be sufficient
enough to show an effect [60]. An article reviewed the in-
fluence of preventive measures on PAM during a decade,
effectively 2002 to 2012, and reported placental malaria
rates ranging from 2 to 29% among women treated with
less than three doses (mainly two) of sulphadoxine-pyrimethamine (SP) compared to 2 to 8% among women
receiving more than or equal three doses (mainly three)
[60]. A novel study included within the afore mentioned re-
view describes a two-fold lower prevalence of placental
malaria in the three-dose SP group compared to the two-
dose SP group (adjusted prevalence ratio = 0.48) [61]. Even
if the augmented efficacy associated with higher doses is
predominately observed in clinical trials rather than in
studies of public health programme implementations [60],
the emergence of SP resistance is certainly shaping the effi-
cacy of IPTp, and consequently its influence on the malaria
burden in infants.
IPTp and malaria in infants: when protection encounters
resistance
Reduced compliance with drug regimes and the increas-
ing resistance to anti-malaria drugs highlight the com-
plexity of IPTp management at present. A 2007 meta-
analysis confirmed that SP IPTp continued to benefit
pregnant women in areas of up to 39% resistance to SP,
measured by in vivo resistance at day 14 of treatment in
children [56]. Similar results were found in Benin, where
rates of in vivo resistance to SP were estimated to be
50% by day 28 of treatment in infants, and yet SP IPTp
succeeded to prevent LBW [62]. However, studies pub-
lished more recently display contradictory results. A
study in Malawi, where there is a strong fixation of the
resistant quintuple mutant, shows significantly reduced
small for gestational age (SGA) rates in offspring of pri-
migravid women having received ≥2 doses of SP com-
pared to 0-1 doses [63]. On the other hand, peripheral
parasitaemia was is significantly higher among women
having received ≥2 doses of SP. Indeed, the effects of re-
sistance on malaria clinical outcomes become more fre-
quent in more recent studies from East Africa. In a
Tanzanian site with high SP resistance (14-day parasito-
logic SP treatment failure rate in children of 68%), IPTp
was not associated with a reduction in odds of PM,
LBW or maternal anaemia. Furthermore, it was associ-
ated with increased odds of foetal anaemia and severe
malaria among the offspring (AOR = 2.31) [64]. IPTp in
this setting was associated with an overall increased risk
of severe malaria [64,65].
However a recent longitudinal study revealed no sig-
nificant increase of malaria at delivery after IPTp treat-
ment, albeit the increasing prevalence and fixation of
SP-resistant P. falciparum haplotypes in another area in
Malawi [66]. Evidence for the present efficacy of SP-
IPTp regimes is inconclusive but resistance to SP is
spreading. Close monitoring of its efficacy is therefore
necessary to determine if or when the treatment failure
of SP-IPTp detected by some recent studies has become
generalized at the population level, thus necessitating a
switch to alternative drug regimes. Nevertheless, the
Figure 1 Intermittent Preventive Treatment in pregnancy in Africa. Source: World Malaria report 2013. WHO publications 2013. A. Implementation of
intermittent preventive treatment in pregnancy in Africa. B. The percentages of women having received at least 2 doses of IPTp are approximated
data issue of the latest demographic surveys of the countries represented.
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current paucity of data in order to determine the precise
level of resistance obliging interruption of IPTp-SP treat-
ment, especially in the absence of an established and ef-
fective alternative [55].
Currently, the Intermittent Screening and Treatment
(IST) is a proposed alternative to IPTp in areas with
substantial resistance against IPTp regimes. IST consists
in screening for malaria infection using a malaria rapid
diagnostic test (RDT) at scheduled antenatal clinic visits
and subsequently treating positive women with an effect-
ive anti-malarial drug [67]. However, extensive evidence
on IST efficacy is lacking in African regions and further
efficacy studies should be conducted in broader geo-
graphical regions [68].
In summary, PAM determines foetal exposure to P.
falciparum in utero and is hence correlated to congenital
malaria and earlier development of clinical episodes in
infancy, possibly as the consequence of an immune tol-
erance process in utero. Effective IPTp diminishes PM
and malaria associated morbidity such as LBW, pre-
term delivery, IUGR, and perinatal mortality in areas
where resistance to SP is not highly significant. Yet the
influence of different IPTp regimes on malaria morbidity
in infants remains a question for further research. The
concrete effect of resistance and the ongoing immune
tolerance process in utero have not been presently ex-
plored. Further evidence is also lacking on the import-
ance of the timing of infection during pregnancy and
infant malaria morbidity. There exists some evidence
that earlier administration of IPTp has a positive effect
on birth outcomes like LBW, nevertheless, later dosing
provides a more continuous protection [50], thus neces-
sitating the administration of three doses instead of two
for improved clinical outcomes. In addition, the imple-
mentation of different IPTp regimes should be adapted
according to transmission and the SP-resistance pattern.
For example, IST has been applied successfully in an
area of moderately high malaria transmission in Ghana
[67]. IST should be further explored and its efficacy
should be evaluated in other transmission settings to as-
certain its utility as an effective tool for the control of
PAM.
Conclusions
This review on the impact of PAM on malaria in infants
substantiates the complexity of the subject and the neces-
sity of a holistic approach for fighting malaria. In addition,
research gaps should be fulfilled to enhance malaria out-
comes. Strategies should start during the pre-conceptual
period or at least during pregnancy, as there is evidence of
increased infant susceptibility to parasites carrying antigens
to which they were previously exposed while in utero. A
complete explanation of the immune process remains aquestion for further research as well as the precise effect of
the timing of in utero exposure to the parasite. Further-
more, the role of protective maternal antibodies has not yet
been clarified. Operational research on different preventive
IPT strategies should also be continuously conducted, and
cost effectiveness analysis for community-level IST inter-
ventions should be investigated.
Finally, novel aspects of research on PAM should be
further explored. Due to the long-term impact of placen-
tal malaria’s possible neuro-cognitive consequences, the
scientific community should prioritize studies investigat-
ing this interaction. An exploration of the influence of
HLA-G polymorphisms on subsequent malaria symp-
toms would serve as well as an important contribution
for infant malaria risk factors.
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